NovaBay Pharmaceuticals sold its Avenova eyecare brand and related assets to PRN for $11.5 million, with plans for liquidation pending stockholder approval. The company is also providing transition services to PRN and has adjourned a meeting to further solicit votes for its liquidation plan.